Welcome to our dedicated page for Evotec SE SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Evotec SE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Evotec SE's regulatory disclosures and financial reporting.
Evotec SE (EVO) reported that its wholly owned biologics CDMO subsidiary, Just – Evotec Biologics, has initiated a Phase 1 clinical trial of JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses. The program was developed under the U.S. Department of War’s Accelerated Antibodies Program, moving from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical material at the J.POD® facility in Redmond, Washington using a continuous bioprocessing platform.
The orthopoxvirus program is the second awarded to Just – Evotec Biologics under this U.S. government framework and, together with an earlier 2022 plague antibody program, has a combined potential contract value of up to $123.9 million. JST-018 is being developed as a prophylactic therapy intended to help protect warfighters at elevated risk of exposure to biological threats, and the Phase 1 study is listed on ClinicalTrials.gov under identifier NCT07595458.
Evotec SE reports a weak first half of 2026, with Group revenue down 19.2% to €300.1 m from €371.2 m, reflecting softer customer demand, weaker sales-to-revenue conversion and the non-repeat of a large Sandoz license deal. At constant exchange rates, revenue was €313.2 m. Gross margin turned to (1.0)% from 13.6%, as underutilisation in Discovery & Preclinical Development (D&PD) and negative mix effects in Just – Evotec Biologics (JEB) weighed on profitability.
Other operating expenses surged to €51.2 m, including a €42.3 m impairment on a Hamburg lab building, and reorganization costs linked to Project Horizon reached €98.9 m. Adjusted Group EBITDA declined to a loss of €42.7 m versus a €1.9 m loss a year earlier, and net loss widened to €168.6 m from €75.1 m. Operating cash flow was negative €111.1 m. These effects were partly offset by a €71.9 m gain from the sale of Tubulis GmbH and tight control of R&D and SG&A spending.
Total liquidity stood at €465.6 m, supported by €116.1 m of new senior unsecured convertible bonds to finance Horizon. The equity ratio fell to 42.3%. Updated 2026 guidance now targets revenue of €570–610 m and adjusted EBITDA of €(70) to €(105) m, materially below previous ranges, mainly due to lower-than-expected strategic partnership and milestone contributions, with some revenues shifting into 2027.
Evotec SE reported preliminary unaudited results showing first-half 2026 Group revenues of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million, with liquidity of about €465.6 million as of 30 June 2026.
Evotec reduced its full-year 2026 outlook to Group revenues of approximately €570 to 610 million and adjusted Group EBITDA of about -€70 to -105 million, compared with prior guidance of €700–780 million and €0–40 million, respectively. Around 40% of the revenue gap reflects milestone phasing into 2027, 45% lower-than-anticipated new strategic partnerships, and 15% weaker revenue conversion. Preliminary segment data show year-on-year revenue declines in Discovery & Preclinical Development and Just – Evotec Biologics in Q2 and H1 2026, though management highlights stronger sales momentum in the base CRO and CDMO business and ongoing “Horizon” cost measures targeting about €75 million in annual run-rate savings by end-2027.
Evotec SE filed a Form 6-K as a foreign private issuer to report a directors’ dealing by Dr. Cord Dohrmann. The filing states that on June 16, 2026, the company submitted a directors’ dealing notice for a transaction in which Dr. Dohrmann sold shares, detailed in Exhibit 99.1. This is an administrative disclosure and does not include financial results or guidance.
Evotec SE reported a sharp downturn in first‑quarter 2026 results while advancing a major restructuring and strategic review. Group revenue fell 21.7% to €156.6 million, or €166.9 million at constant exchange rates, mainly because Q1 2025 included a large Sandoz license payment and markets for early discovery remained soft.
Cost controls reduced R&D to €10.1 million and SG&A to €43.8 million, but a €75.0 million reorganization charge under the Horizon program pushed operating loss to €121.4 million and net loss to €121.9 million, or €0.69 per share. Adjusted Group EBITDA swung from €3.1 million profit to a €21.9 million loss.
Horizon aims to streamline Evotec’s footprint to ten sites and deliver about €75 million of structural annual savings by the end of 2027, with 20–30% expected in 2026. Despite the loss, liquidity remained sizeable at €444.8 million. After quarter‑end, Evotec agreed to receive about $100 million upfront, plus up to $58 million in milestones, from the sale of its minority stake in Tubulis to Gilead, and installed a new CFO and COO. Full‑year 2026 guidance was reaffirmed.
Evotec SE received an updated ownership and cooperation disclosure from MAK Capital Fund and related parties. The group reports beneficial ownership of 12,681,898 Ordinary Shares, representing about 7.1% of Evotec’s 177,877,782 outstanding Ordinary Shares and ADS-equivalent shares as of May 1, 2026.
MAK Fund bought these shares in open-market transactions for an aggregate purchase price of approximately 73,333,274 euros, excluding commissions. MAK and Evotec entered into a cooperation agreement on April 29, 2026, under which Evotec will nominate Dr. Wolfgang Hofmann to its Supervisory Board at the June 11, 2026 AGM, and the agenda includes increasing the Supervisory Board from six to seven members. MAK Fund agreed to customary voting and cooperation commitments, including supporting board expansion and the issuer’s nominees for the open seats.
Evotec SE filed an update on corporate governance, highlighting board nominations and a new shareholder agreement. The company has nominated Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the Annual General Meeting on 11 June 2026. The agenda also includes the previously announced nomination of Dieter Weinand as Chairman and a proposal to expand the Supervisory Board from six to seven members.
Evotec has entered into a cooperation agreement with key shareholder MAK Capital Fund LP, which includes customary voting and cooperation commitments. Both Evotec’s Supervisory Board leadership and MAK Capital emphasize constructive shareholder engagement to support the company’s ongoing transformation and long‑term success.
Evotec SE reports that its Chief Financial Officer Paul Hitchin will step down on April 30, 2026 for personal reasons described as unrelated to the company. Hitchin, who has served as CFO since March 1, 2025, is credited with guiding Evotec through a significant financial and strategic evolution and supporting a broader company transformation.
Claire Hinshelwood has been appointed as the new CFO effective May 1, 2026. She brings more than 30 years of financial leadership experience, including roles as Group Chief Finance Officer of BMI Group, Global Head of Finance Operations at Novartis, and senior finance roles at Syngenta. Evotec’s CEO and both CFOs emphasize continuity in executing the company’s transformation plan aimed at increased profitability, sustainable growth, and value creation.
Evotec SE reported fourth quarter and full-year 2025 results showing stronger profitability despite slightly lower annual revenue. Q4 Group revenues were €253.3 million, up 14% year-on-year, while adjusted Group EBITDA more than doubled to €58.0 million, helped by a license payment under the Sandoz agreement.
For full-year 2025, Group revenues were €788.4 million, a modest 1.1% decline, but adjusted Group EBITDA rose to €41.1 million from €22.6 million as cost discipline delivered structural savings of €60 million. Liquidity at year-end stood at €476 million, reflecting a net cash position.
Segment trends diverged: Drug Discovery & Preclinical Development revenues fell 13.5% to €528.9 million with negative adjusted EBITDA, while Just – Evotec Biologics revenues grew 39% to €259.4 million and adjusted EBITDA rose to €53.2 million, supported by the Sandoz transaction valued at more than $650 million. The company launched its Horizon operating model to streamline sites, create Centers of Excellence and target about €75 million of structural cost savings by the end of 2027.